Clinical implications of novel mutations in epigenetic modifiers in AML.

Abstract excerpt

The studies highlighted in this article suggest that mutations in TET2 mutations may impart adverse outcome in patients with CN-AML, whereas mutations in DNMT3a may have adverse implications in a broader set of patients with AML. The data with IDH enzyme mutations are less clear, in that individual IDH1 and IDH2 mutations may have different clinical effects and the data so far have not suggested a uniform effect...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Dioxygenases
• Share to DNA (Cytosine-5-)-Methyltransferases
• Share to DNA Methyltransferase 3A